The global incidence of gastrointestinal and hepatic diseases has been gradually increasing in recent years, which seriously threatens human health and increases the economic burden. More importantly, gastrointestinal and hepatic malignancies have the highest incidence and mortality rates among all tumors, such as liver cancer, stomach cancer, colon cancer, and pancreatic cancer. There are also non-neoplastic diseases such as viral hepatitis, cirrhosis, nonalcoholic steatohepatitis, chronic atrophic gastritis, ulcerative colitis, and reflux esophageal disease that also affect patients' quality of life. Although progress has been made in the pathogenesis of gastrointestinal and hepatic diseases, and corresponding therapeutic drugs have been also developed, the specific mechanisms of the diseases are still not revealed and there is a lack of specific drugs. In view of this, this topic aims to explore new molecular mechanisms of pathogenesis and potential therapeutic agents and pharmacological effects of gastrointestinal and hepatic diseases.

Chronic liver failure is a frequent condition in clinical practice that encompasses all manifestations of patients with end-stage liver diseases. Chronic liver failure is a multiorgan syndrome that affects the liver, kidneys, brain, heart, lungs, adrenal glands, and vascular, coagulation, and immune systems. Chronic Liver Failure: Mechanisms and Management covers for the first time all aspects of chronic liver failure in a single book, from pathogenesis to current management. Each chapter is written by a worldwide known expert in their area and all provide the latest state-of-the-art knowledge. This volume is specifically designed to provide answers to clinical questions to all doctors dealing with patients with liver diseases, not only clinical gastroenterologists and hepatologists, but also to internists, nephrologists, intensive care physicians, and transplant surgeons.

Since the publication of the first edition, there have been advances in both the diagnosis and the management of many of the cholestatic liver diseases. Cholestatic Liver Disease, Second Edition thoroughly updates the topics previously addressed, such as primary biliary cirrhosis, primary sclerosing cholangitis and cholestatic variants of drug hepatotoxicity and viral disease. New treatments, such as the development of the farnesoid X receptor agonists for the treatment of PBC, are highlighted. Current guidelines and areas of uncertainty are also covered. Additionally, new chapters have been added to reflect the changing landscape of cholestatic liver disease. Cholestatic Liver Disease, Second Edition is a concise yet comprehensive summary of the current status of the field and is of value to clinicians and researchers interested in patients with cholestatic liver disease provide that will help to guide patient management and stimulate investigative efforts.

Drug-Induced Liver Injury, Volume 85, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field. Chapters in this new release include Cell death mechanisms in DILI, Mitochondria in DILI, Primary hepatocytes and their cultures for the testing of drug-induced liver injury, MetaHeps an alternate approach to identify IDILI, Autophagy and DILI, Biomarkers and DILI, Regeneration and DILI, Drug-induced liver injury in obesity and nonalcoholic fatty liver disease, Mechanisms of Idiosyncratic Drug-Induced Liver Injury, the Evaluation and Treatment of Acetaminophen Toxicity, and much more. - Includes the authority and expertise of leading contributors in pharmacology - Presents the latest release in the Advances in Pharmacology series

This unique book deals with both inflammation and cancer in a single source of publication. They are seldom grouped together although it has been known that both diseases are closely associated, particularly in the gastrointestinal tract and liver. As the book touches on two such major areas of diseases in humans, it should be of interest to a wider audience of researchers and readers. It is noted that the book combines the effort of both basic scientists and clinicians from different countries with extensive experiences in molecular biology and clinical practice to unveil the most updated picture of the pathogenesis and therapeutic strategies in the treatment of inflammation and cancer in the digestive tract. In this regard, potential pathogenic modulators and also therapeutic options are widely discussed. These types of information would definitely broaden our knowledge in better understanding these diseases.